WallStSmart
XERS

Xeris Pharmaceuticals Inc

NASDAQ: XERS · HEALTHCARE · BIOTECHNOLOGY

$6.13
+1.74% today

Updated 2026-04-30

Market cap
$1.04B
P/E ratio
0.00
P/S ratio
3.56x
EPS (TTM)
$0.00
Dividend yield
52W range
$4 – $10
Volume
1.9M

Xeris Pharmaceuticals Inc (XERS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
Last 4 quarters
Revenue YoY growth
+42.8%
Most recent quarter
EPS YoY growth
+300.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-1.0%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-24.7%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-02$0.06+261.4%$6.12$5.94-2.9%
2025-11-06$0.00-65.0%$9.87$7.43-24.7%
2025-08-07$-0.01+66.7%$5.49$6.84+24.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.02$0.06+261.4%$85.81M+42.8%
2025-09-30$0.01$0.00-65.0%$74.38M+37.1%
2025-06-30$-0.03$-0.01+66.7%$71.54M+48.8%
2025-03-31$-0.04$-0.06-50.0%$60.12M+47.9%
2024-12-31$-0.02$-0.03-50.0%$60.10M+35.4%
2024-09-30$-0.09$-0.11-22.2%$54.27M+12.3%
2024-06-30$-0.11$-0.10+9.1%$48.06M+26.5%
2024-03-31$-0.12$-0.14-16.7%$40.64M
2023-12-31$-0.10$-0.10+0.0%$44.39M
2023-09-30$-0.12$-0.09+25.0%$48.32M
2023-06-30$-0.13$-0.14-7.7%$38.01M

Frequently asked questions

Has Xeris Pharmaceuticals Inc beaten earnings estimates?
Xeris Pharmaceuticals Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports.
How does XERS stock react to earnings?
XERS stock has moved an average of -1.0% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Xeris Pharmaceuticals Inc's revenue growth rate?
Xeris Pharmaceuticals Inc reported year-over-year revenue growth of +42.8% in its most recent quarter, with EPS growing +300.0% year-over-year.